Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F520 in advanced or recurrent cervical cancer
CTR20202433Phase 2Completed
- Sponsor
- Shandong New Era Pharmaceutical
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of rulonilimab in Cervical Cancer (CC), sponsored by Shandong New Era Pharmaceutical. Started Dec 2020; status: completed.
02
Drugs
rulonilimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20202433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202433.